We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 1.59 | 6.21% | 27.21 | 27.45 | 26.02 | 26.3295 | 97,521,966 | 00:59:15 |
From May 2019 to May 2024
By Cara Lombardo
Chantix, a medication from Pfizer Inc. (PFE) used to help people quit smoking, failed in a study designed to test its effectiveness on smokers between the ages of 12 and 19.
The study examined the safety and efficacy of varenicline, marketed in the U.S. as Chantix, for smoking cessation in nicotine-dependent preteens and teens. When compared to a placebo, Chantix didn't meet the primary endpoint of a four-week continuous abstinence rate in the final weeks of the 12-week study, Pfizer said Friday.
Chantix, known as Champix in Europe and other countries, was approved by the U.S. Food and Drug Administration in 2006 to help adults quit smoking.
The study was a regulatory post-marketing commitment for Chantix and Champix in the U.S. and Europe. The study data will be submitted to the FDA for pediatric exclusivity determination, Pfizer said.
Pfizer shares fell 1% in premarket trading.
Write to Cara Lombardo at cara.lombardo@wsj.com
(END) Dow Jones Newswires
March 23, 2018 08:55 ET (12:55 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
